These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 36049834)

  • 1. The Molecular Pathogenesis and Targeted Therapies for Cholangiocarcinoma.
    Param NJ; Bramel ER; Sia D
    Surg Pathol Clin; 2022 Sep; 15(3):529-539. PubMed ID: 36049834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance.
    Fouassier L; Marzioni M; Afonso MB; Dooley S; Gaston K; Giannelli G; Rodrigues CMP; Lozano E; Mancarella S; Segatto O; Vaquero J; Marin JJG; Coulouarn C
    Liver Int; 2019 May; 39 Suppl 1():43-62. PubMed ID: 30903728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
    Braconi C; Roessler S; Kruk B; Lammert F; Krawczyk M; Andersen JB
    Liver Int; 2019 May; 39 Suppl 1():32-42. PubMed ID: 30829432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholangiocarcinoma: molecular pathways and therapeutic opportunities.
    Ilyas SI; Borad MJ; Patel T; Gores GJ
    Semin Liver Dis; 2014 Nov; 34(4):456-64. PubMed ID: 25369307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications.
    Kankeu Fonkoua LA; Serrano Uson Junior PL; Mody K; Mahipal A; Borad MJ; Roberts LR
    Expert Opin Ther Targets; 2022 Jan; 26(1):79-92. PubMed ID: 35034558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
    Borad MJ; Gores GJ; Roberts LR
    Curr Opin Gastroenterol; 2015 May; 31(3):264-8. PubMed ID: 25763789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
    Rizzo A
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34066684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
    Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
    Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging molecular therapeutic targets for cholangiocarcinoma.
    Ilyas SI; Gores GJ
    J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma.
    Saborowski A; Vogel A; Segatto O
    Trends Cancer; 2022 Feb; 8(2):83-86. PubMed ID: 34840108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of molecular genetics in the clinical management of cholangiocarcinoma.
    Normanno N; Martinelli E; Melisi D; Pinto C; Rimassa L; Santini D; Scarpa A
    ESMO Open; 2022 Jun; 7(3):100505. PubMed ID: 35696744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
    King G; Javle M
    Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in targeted therapy of cholangiocarcinoma.
    Li Y; Yu J; Zhang Y; Peng C; Song Y; Liu S
    Ann Med; 2024 Dec; 56(1):2310196. PubMed ID: 38359439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular therapeutic targets for cholangiocarcinoma: Present challenges and future possibilities.
    Høgdall D; O'Rourke CJ; Andersen JB
    Adv Cancer Res; 2022; 156():343-366. PubMed ID: 35961705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecularly Guided Drug Repurposing for Cholangiocarcinoma: An Integrative Bioinformatic Approach.
    Venkatraman S; Balasubramanian B; Pongchaikul P; Tohtong R; Chutipongtanate S
    Genes (Basel); 2022 Jan; 13(2):. PubMed ID: 35205315
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Angerilli V; Fornaro L; Pepe F; Rossi SM; Perrone G; Malapelle U; Fassan M
    Pathologica; 2023 Apr; 115(2):71-82. PubMed ID: 37017301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways.
    Kongpetch S; Jusakul A; Ong CK; Lim WK; Rozen SG; Tan P; Teh BT
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):233-44. PubMed ID: 25966424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathways of genetic transformation in cholangiocarcinogenesis.
    Serafini FM; Radvinsky D
    Cancer Genet; 2016 Dec; 209(12):554-558. PubMed ID: 27720541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach.
    Merath K; Tiwari A; Parikh AA; Pawlik TM
    Future Oncol; 2023 Dec; 19(39):2607-2621. PubMed ID: 38108100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular aspects of cholangiocarcinoma.
    Kiguchi K
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):371-9. PubMed ID: 24420749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.